Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 24 July 2024 PM
DNA giant Illumina is getting behind Incannex's psilocybin candidate, offering its genomic technologies to a Monash research team investigating the drug to treat generalised anxiety disorder (GAD).
Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health has been named the winner of the annual Australasian Neuroscience Society (ANS) Illumia Neurogenomics Research Award.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.